Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Refractory Solid Tumors
NCT02691767Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pazopanib in solid tumor, sponsored by Samsung Medical Center. Primary endpoint: Progression-free survival at 24 months. Started May 2016; status: completed.
02
Drugs
pazopanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02691767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691767.